Source:

Journal of the Dermatology Nurses' Association

April 2009, Volume 1 Number 2 , p 145 - 146 [FREE]

Authors

  • Alan Menter MD
  • Luz E. Colon MS, CCRC, CCRA
  • Lori Johnson PhD
  • Ron Gottschalk MD

Abstract

function set_JnlFullText_Print() { metaTag = document.createElement('meta'); metaTag.setAttribute('name','OvidPageId'); metaTag.setAttribute('content','JnlFullText_Print'); head = document.getElementsByTagName('head')[0]; head.appendChild(metaTag); return; } if (window.addEventListener) { // DOM Level 2 Event Module (NS 6+) // Firefox throws an uncaught exception error executing this // code, even though it seems to work. Adding a do nothing // try/catch clause around it for now, since the exection itself // appears to be innocuous try { window.addEventListener('onload',set_JnlFullText_Print(),false); } catch(e) {} } else if (window.attachEvent) { // IE 5+ Event Model window.attachEvent('onload',set_JnlFullText_Print); } // For anything else, just don't add the event Print Close Journal of the Dermatology Nurses' Association Clobetasol Propionate 0.05% Spray vs Calcipotriene 0.005%, Betamethasone Dipropionate 0.064% Ointment for the Treatment of Plaque Psoriasis: Results from a Randomized Study DOI: 10.1097/01.JDN.0000350426.15992.5c ISSN: 1945-760X Accession: 01412499-200903000-00026 Author(s):

Menter, Alan MD 1 ; Colon, Luz E. MS, CCRC, CCRA 2 ; Johnson, Lori PhD 2 ; Gottschalk, Ron MD 2

Issue: Volume 1(2), March/April 2009, pp 145-146 Publication Type: [DEPARTMENTS: 2009 Conference Abstracts] Publisher: © 2009 Lippincott Williams & Wilkins, Inc. Institution(s): 1 Baylor University Medical Center, Dallas, TX 2 Galderma Laboratories, L.P., Fort Worth, TX INTRODUCTION

Topical corticosteroids including clobetasol propionate have been widely used in the treatment of psoriasis since the 1950s. Similar efficacy successes have been reported following 2 weeks of treatment with clobetasol propionate 0.05% (CP) spray or 4 weeks of treatment with calcipotriene 0.005%, betamethasone dipropionate 0.064% (C-BD) ointment in separate studies. Greater efficacy has been noted with clobetasol propionate 0.05% spray when used for 4 weeks ...

INTRODUCTION

 

Topical corticosteroids including clobetasol propionate have been widely used in the treatment of psoriasis since the 1950s. Similar efficacy successes have been reported following 2 weeks of treatment with clobetasol propionate 0.05% (CP) spray or 4 weeks of treatment with calcipotriene 0.005%, betamethasone dipropionate 0.064% (C-BD) ointment in separate studies. Greater efficacy has been noted with clobetasol propionate 0.05% spray when used for 4 weeks compared with 2 weeks with an acceptable safety profile. Clobetasol propionate 0.05% spray and calcipotriene 0.005%, betamethasone dipropionate 0.064% ointment have not previously been directly compared for efficacy and safety in the same study.

METHODS

 

It was therefore the aim of this study to compare the efficacy and safety of clobetasol propionate 0.05% spray to calcipotriene 0.005%, betamethasone dipropionate 0.064% ointment in patients with moderate to severe plaque psoriasis for a period of up to 4 weeks. Assessments were made at baseline, Week 2, Week 4 (end of treatment) and Week 8 (4 weeks post treatment).

RESULTS

 

An assessment for overall disease severity (ODS) found that 75% of CP-spray-treated patients (p =.003) achieved a rating of clear or almost clear after 4 weeks of treatment compared with 45% of C-BD-ointment-treated patients. Adverse events were reported by less than one third of patients from each treatment group (31% for CP spray and 33% for C-BD ointment).

CONCLUSIONS

 

The results of this randomized 4-week comparative study are expected to provide further information to dermatologists considering treatment choices for psoriasis patients who are candidates for topical corticosteroid therapy.

NURSING IMPLICATIONS

 

Nurses in the specialized field of dermatology will gain insight into the disease state and treatment options, which will be useful information for patient consultations.

REFERENCES

 

Beutner, K., Chakrabarty, A., Lemke, S., & Yu, K. (2006). An intra-individual randomized safety and efficacy comparison of clobetasol propionate 0.05% spray and its vehicle in the treatment of plaque psoriasis. Journal of Drugs in Dermatology, 5(4), 357-360.

 

Feldman, S. R., Koo, J. Y., Menter, A., & Bagel, J. (2005). Decision points for the initiation of systemic treatment for psoriasis. Journal of the American Academy of Dermatology, 53(1), 101-107.

 

Guenther, L., Van de Kerkhof, P. C., Snellman, E., Kragballe, K., Chu, A.C., Tegner, E., et al. (2002). Efficacy and safety of a new combination of calcipotriol and betamethasone dipropionate (once or twice daily) compared to calcipotriol (twice daily) in the treatment of psoriasis vulgaris: A randomized, double-blind, vehicle-controlled clinical trial. British Journal of Dermatology, 147(2), 316-323.

 

Jarratt, M. T., Clark, S. D., Savin, R. C., Swinyer, L. J., Safley, C. F., Brodell, R. T., et al. (2006). Evaluation of the efficacy and safety of clobetasol propionate spray in the treatment of plaque-type psoriasis. Cutis, 78(5), 348-354.

 

Kiec-Swierczynska, M., Dudek, B., Krecisz, B., Swierczynska-Machura, D., Dudek, W., Garnczarek, A., et al. (2006). [The role of psychological factors and psychiatric disorders in skin diseases]. Medycyna Pracy, 57(6), 551-555.

 

Kragballe, K., Austad, J., Barnes, L., Bibby, A., de la Brassinne, M., Cambazard, F., et al. (2006). Efficacy results of a 52-week, randomised, double-blind, safety study of a calcipotriol/betamethasone dipropionate two-compound product (Daivobet/Dovobet/Taclonex) in the treatment of psoriasis vulgaris. Dermatology, 213(4), 319-326.

 

Kragballe, K., & van de Kerkhof, P. C. (2006). Consistency of data in six Phase III clinical studies of a two-compound product containing calcipotriol and betamethasone dipropionate ointment for the treatment of psoriasis. Journal of the European Academy of Dermatology and Venereology, 20(1), 39-44.

 

Menter, A., & Griffiths, C. E. (2007). Current and future management of psoriasis. Lancet, 370(9583), 272-284.

 

van de Kerkhof, P. C. (2003). Psoriasis. St. Louis, MO: Mosby.